177lu-pp-f11n
Small moleculeexperimentalImaging agent
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2015 (NCT02088645)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 177-lutetium
Oral
No
Parenteral
No
Topical
No
Also known as
- 177lu-pp-f11n
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03647657 | Early Phase 1 (Phase 1) | Oct 31, 2018 | Krebsforschung Schweiz, Bern, Switzerland, Paul Scherrer Institute, Villigen, Switzerland, University of Basel, University of Freiburg, University of Zurich |
| NCT02088645 | Phase 1 | Apr 1, 2015 | Krebsforschung Schweiz, Bern, Switzerland, Paul Scherrer Institute, Villigen, Switzerland, University of Bern, University of Freiburg |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Krebsforschung Schweiz, Bern, Switzerland | Academic/Hospital | 2 | 0 | 1 | 2015 |
| Paul Scherrer Institute, Villigen, Switzerland | Academic/Hospital | 2 | 0 | 1 | 2015 |
| University of Freiburg | Academic/Hospital | 2 | 0 | 1 | 2015 |
| University of Basel | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Bern | Academic/Hospital | 1 | 1 | 1 | 2015 |
| University of Zurich | Academic/Hospital | 1 | 0 | 1 | 2018 |
6 organizations
Page 1 / 1